Calls
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-05-07 · generated 2026-07-26.
Latest call digest
Vital Farms, Inc., Q1 2026 Earnings Call, May 07, 2026 · 2026-05-07T12:30:00
Q1 2026 call (May 7, 2026). The prepared remarks were a guidance reset. Management cut FY2026 net-sales guidance to $775 million to $800 million and adjusted EBITDA to $0 million to $10 million, down from the $900 million to $920 million and $105 million to $115 million set three months earlier, citing price gaps that reached "levels that our brand could not sustain." First-quarter net revenue still grew 15.4% to $187.2 million, but gross margin fell to 28.3% from 38.5% a year earlier and adjusted EBITDA dropped to $5 million. Management laid out a five-part self-help plan: right-sizing farmer supply (via paid contract amendments plus low- or no-revenue breaker-channel sales), reducing COGS (about $4 million of ECS staffing), managing SG&A (eliminating roughly 10% of remote headcount), controlling CapEx (about $75 million lower, mainly by slowing the Vital Crossroads / Seymour build and pausing accelerator farms) and exiting the butter business. The Q&A was harder-edged than the "reset of our expectations, not a reset of our ambitions" framing. Analysts pressed on the cash bridge and covenants (a revolver draw is now planned), where Q2 EBITDA bottoms (negative, mid- to high-teens), the credibility of a 2027 return to double-digit EBITDA margins, and the wisdom of exiting butter and slow-rolling Seymour. Notably, the company still repurchased over 1 million shares for $20 million in the quarter and continued to tout distribution wins (TDPs ending Q1 at 149.8, targeting 170 to 175 by Q4).
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Brian Shipman — VP & Head of Investor Relations, Vital Farms, Inc.; Russell Diez-Canseco — President, CEO & Executive Chairperson, Vital Farms, Inc.; Thilo Wrede — CFO, Chief Accounting Officer & principal accounting officer, Vital Farms, Inc.; Brian S. Shipman | 5 |
| Analysts | Matthew Smith — Associate Analyst, Stifel, Nicolaus & Company, Incorporated, Research Division; Eric Des Lauriers — Senior Research Analyst, Craig-Hallum Capital Group LLC, Research Division; Brian Holland — MD & Senior Research Analyst, D.A. Davidson & Co., Research Division; Robert Moskow — Managing Director and Food & Beverages, TD Cowen, Research Division; Glenn West — Research Analyst, William Blair & Company L.L.C., Research Division; Benjamin Mayhew — VP & Associate, BMO Capital Markets Equity Research; Benjamin Klieve — Research Analyst, The Benchmark Company, LLC, Research Division; Scott Marks — Equity Analyst, Jefferies LLC, Research Division; John Baumgartner — Former MD & Senior Consumer Equity Research Analyst, Mizuho Securities USA LLC, Research Division; Megan Christine Alexander — VP & Equity Analyst, Morgan Stanley, Research Division | 10 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Matthew Smith | Stifel, Nicolaus & Company | Long-term margin credibility | Asked whether the double-digit EBITDA target still holds if today's distressed pricing becomes the new normal; management said it is not waiting on an industry price recovery to restore gross and EBITDA margins. |
| Eric Des Lauriers | Craig-Hallum Capital Group | Liquidity and covenants | Questioned the cash bridge given about $51 million of cash against planned CapEx; management confirmed it will start using the revolver, cited a 3.5x net-leverage and 1.35x fixed-charge covenant, and said talks with JPMorgan are ongoing. |
| Brian Holland | D.A. Davidson | Where EBITDA bottoms | Pushed for a tighter Q2 trough; the CFO pointed to negative EBITDA in the mid- to high-teens, with the majority of the $32 million of supply-management cost hitting Q2. |
| Robert Moskow | TD Cowen | Butter exit | Challenged the decision to exit butter and step back from shelf, asking about licensing alternatives; management framed it as refocusing capital and management on the higher-advantage egg business. |
| Benjamin Mayhew | BMO Capital Markets | Vital Crossroads pause | Asked how long construction can be slow-rolled while return economics still work; management said it can restart and finish in under a year and that ECS still supports roughly $1 billion of revenue. |
| Megan Christine Alexander | Morgan Stanley | Volume-recovery drivers | Probed how much of the second-half volume inflection comes from closing price gaps versus new distribution, and how long velocities take to normalize; management leaned on distribution gains activated by recovering velocities. |
| John Baumgartner | Mizuho Securities | Buy rate vs. new-household trial | Asked where the pressure sits; management said existing consumers' buy rates are holding and even up slightly, and the shortfall is in first-time household trial. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| Price gaps to premium competitors | persisted | Q2 2024, Q3 2024, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | Discussed nearly every quarter, but the message inverted. Management dismissed price gaps as having very limited impact through late 2025, then in Q1 2026 identified widening gaps as the direct cause of slowing trial and the guidance cut. |
| Egg supply constraints | dropped | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025 | The dominant limiter for a year-plus was not having enough eggs to meet demand. That framing disappeared by Q1 2026 as the problem inverted to oversupply. |
| Managing oversupply | emerged | Q1 2026 | New in Q1 2026: excess volume dumped to the breaker/low- or no-revenue channels and paid farmer contract amendments to cease or delay production, an estimated $32 million cost for the year. |
| Brand awareness converting to trial | persisted | Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | Aided awareness climbed from 26% to 34% over 2025, and the 'convert awareness to trial' refrain recurred throughout. By Q1 2026 the conversion faltered: new-to-brand households fell from over 55% to 50%. |
| Capacity investment (Seymour/VXR, ECS third line, accelerator farms) | persisted | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | Aggressive build-out (two Seymour lines concurrently, CapEx pulled forward, third ECS line) through Q4 2025, then a sharp reversal in Q1 2026: Seymour slowed, accelerator farms paused, CapEx cut by about $75 million. |
| Tariffs | dropped | Q1 2025, Q2 2025, Q3 2025 | Prominent in mid-2025 and the stated rationale for the May 2025 price increase; impact was called more modest than feared by Q3 2025 and faded thereafter, resurfacing only as one reason to exit butter's international supply chain. |
| Share repurchase program | emerged | Q4 2025, Q1 2026 | First-ever buyback ($100 million, two years) authorized in Q4 2025; the company executed $20 million in Q1 2026 even as it moved toward drawing the revolver. |
| Butter business | dropped | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q4 2025, Q1 2026 | Relaunched from Irish supply in 2024 and repeatedly cited as a growth pillar; the company announced a full exit in Q1 2026, ending shipments toward year-end. |
| Family farm network expansion | persisted | Q2 2024, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025 | Steady recruitment (roughly 350 farms in mid-2024 to more than 600 by end-2025). The relationship reversed in Q1 2026 as the company began paying some farmers to pause production. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “we continue to expect net revenue of at least $740 million or at least 22% growth versus 2024 and adjusted EBITDA of at least $100 million or at least 15% growth” | Vital Farms, Inc., Q1 2025 Earnings Call, May 08, 2025 · 2025-05-08T12:30:00 | Thilo Wrede | kept | FY2025 came in at $759.4 million net revenue and $114 million adjusted EBITDA, both above these at-least floors. |
| “we are raising our full year 2025 net revenue guidance to at least $775 million, representing growth of at least 28% versus 2024” | Vital Farms, Inc., Q3 2025 Earnings Call, Nov 04, 2025 · 2025-11-04T13:30:00 | Thilo Wrede | missed | FY2025 net revenue was reported at $759.4 million, below this at-least-$775 million bar; the outlook was revised down at the December Investor Day. |
| “we're introducing a new net revenue guidance range of $900 million to $920 million, representing more than 20% growth” | Vital Farms, Inc., Q4 2025 Earnings Call, Feb 26, 2026 · 2026-02-26T13:30:00 | Thilo Wrede | missed | Cut three months later to $775 million to $800 million on the Q1 2026 call as price gaps pressured volumes. |
| “we are setting adjusted EBITDA guidance to be within a range of $105 million to $115 million this year” | Vital Farms, Inc., Q4 2025 Earnings Call, Feb 26, 2026 · 2026-02-26T13:30:00 | Thilo Wrede | missed | Slashed to $0 million to $10 million on the Q1 2026 call, reflecting about $32 million of supply-management costs and deeper price investment. |
| “Finally, we expect CapEx of $140 million to $150 million in 2026” | Vital Farms, Inc., Q4 2025 Earnings Call, Feb 26, 2026 · 2026-02-26T13:30:00 | Thilo Wrede | missed | Lowered to $70 million to $75 million on the Q1 2026 call by slowing Vital Crossroads and pausing accelerator-farm construction. |
| “We now expect net revenue of $775 million to $800 million and adjusted EBITDA of $0 million to $10 million” | Vital Farms, Inc., Q1 2026 Earnings Call, May 07, 2026 · 2026-05-07T12:30:00 | Thilo Wrede | pending | The revised FY2026 outlook; no subsequent call in the supplied history to judge the result. |
| “We currently anticipate gross margin to return to 30% by late fourth quarter and underlying adjusted EBITDA margin to get back to double-digits in 2027” | Vital Farms, Inc., Q1 2026 Earnings Call, May 07, 2026 · 2026-05-07T12:30:00 | Thilo Wrede | pending | Forward recovery targets stated in Q1 2026; not yet testable against the supplied call history. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| Margin recovery and where EBITDA bottoms | 3 | Stifel, Nicolaus & Company, D.A. Davidson, Morgan Stanley | On the Q1 2026 call analysts repeatedly probed the credibility of a 2027 return to double-digit EBITDA and the size of the 2026 trough. Management gave the Q2 magnitude (negative, mid- to high-teens) but, on whether the long-term target survives a new-normal environment, reframed rather than reaffirming it directly. |
| Balance sheet, liquidity and covenants | 1 | Craig-Hallum Capital Group | A single but pointed line of questioning on the Q1 2026 call about funding the year; management confirmed it will draw the revolver and disclosed the 3.5x net-leverage and 1.35x fixed-charge covenants. |
| Oversupply management scope and cost | 2 | Stifel, Nicolaus & Company, The Benchmark Company | Analysts pressed on the split between breaker-channel dumping and paid farmer contract amendments and on alternative outlets for excess eggs; management detailed the cadence and the roughly $32 million full-year cost. |
| Price gaps and the path back to volume growth | 3 | D.A. Davidson, Morgan Stanley, Mizuho Securities | Repeated questions on the Q1 2026 call about how much of the second-half recovery comes from narrowing gaps versus new distribution, and whether the pressure is on existing buy rates or first-time trial. |
| Butter exit and Vital Crossroads pause | 2 | TD Cowen, BMO Capital Markets | Analysts questioned exiting a growing butter business and slow-rolling the Seymour facility; management framed both as capital-discipline moves preserving optionality rather than strategy reversals. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| For years management dismissed price gaps as immaterial to demand, a stance held as recently as late 2024. | “price gaps have very limited impact on our demand and our growth opportunity” | 1901683527 | 13 |
| That dismissal persisted into Q3 2025, when the CFO again downplayed gaps even as he acknowledged they had widened. | “what drives our growth is not price gaps” | 1966871927 | 19 |
| In Q1 2026 the language reverses completely, with price gaps named as the cause of the shortfall. | “price gaps reached levels that our brand could not sustain” | 1997151440 | 2 |
| New 'reset' framing enters the vocabulary, distinguishing a lowered near-term outlook from unchanged long-term ambition. | “we see this as a reset of our expectations for 2026, but not a reset of our ambitions” | 1997151440 | 2 |
| The register shifts from growth investment to cost and cash discipline. | “adapting quickly to this new more pressured environment by reducing price gaps, addressing our cost structure and managing cash” | 1997151440 | 2 |
| Management explicitly frames 2026 as a cyclical low point for margins, new caution absent from prior calls. | “we view 2026 as a low watermark for margins in this cycle” | 1997151440 | 2 |
The call history's clearest signal is a reversal: after several years of insisting price gaps were immaterial and running an aggressive, supply-constrained growth build, management conceded in Q1 2026 that gaps had broken trial, slashed 2026 guidance, and pivoted to cost cuts, a butter exit, slowed capacity spend and a revolver draw. The open questions the transcripts leave for the investment debate are execution and credibility, whether the promised 2027 margin recovery and volume reacceleration arrive, and whether the balance sheet is adequate through a first-half-loss year.